OBN (UK) Ltd.. (1/22/19). "Press Release: OBN Announces the Success of 2nd Annual BioSeed 2019". Abingdon.

	Region	London, Greater London
	Country	United Kingdom (GB)
	Organisation	OBN (UK) Ltd.
	Organisation 2	Cambridge Innovation Capital plc (CIC)
	Group	Cambridge Innovation Capital (Group)
	Product	BioSeed 2019 London
	Product 2	venture capital
	Person	Harris, John G. (OBN 201604 CEO)
	Person 2	Tansley, Robert (Cambridge Innovation Capital 201401– Investment Director before KalVista + Avilex Pharma)

OBN (UK) Ltd, the membership organisation that supports the life sciences industry, is delighted to announce the success of their 2nd annual BioSeed® event held on Wednesday, 16 January 2019, at Level 39 in Canary Wharf, London.

The event was a great success and included a packed schedule of quickfire / 5minute presentations from 43 early stage European life sciences companies, who showcased a range of new technologies and treatments to an audience of over 80 high-quality, specialist investors.

The morning session was launched by Tim Mustill, Principal at Astrocyte Consulting, who gave a keynote on what investors look for, along with a case study into the investment he made in CHAIN Biotech, an early-stage firm that pitched at BioSeed 2017.

The day was kindly sponsored by Lonza and included an afternoon of over 500 partnering meetings, an Investor Q&A session and a vibrant evening drinks reception.

John Harris, CEO of OBN said, “We are delighted with the huge success of our 2nd BioSeed event which took place in London. The quality, breadth, and innovative nature of the company presentations (from across Europe) was highly impressive. All presenting companies pitched to a large and high-quality investor audience.

Undoubtedly, BioSeed is now established as the premier UK-based event for early stage funding, genuinely meeting the needs of companies seeking growth capital and investors seeking access to exciting new opportunities.

OBN continues to innovatively support the sustained success and growth of our industry, contributing not only to a strong economy for the UK but also to better long-term patient outcomes across all therapeutic areas.”

OBN have had very positive feedback from investors and presenters who attended.

“A great showcase of early stage companies demonstrating an impressive breadth and depth of innovation. It was well run and an efficient opportunity to see short introductions from over 40 early stage companies in one day.”
Dr Robert Tansley, Operating Partner, Cambridge Innovation Capital

“It was great to see such a wide range of innovation in the UK seed stage bio community with new companies targeting both innovation in therapies and mode of action.”
Oliver Sexton, Investment Director, Midven

"We attended BioSeed to find investors that understand our device and specific health area – not only to invest but to also help grow our business."~
Shelby Temple, Co-founder, Azul Optics

"BioSeed offers a fantastic opportunity to present to a wide range of investors followed by excellent partnering opportunities."
Mike Karim, CEO, Oxford Endovascular

Life sciences companies will have another opportunity to present their innovative technology at BioLaunchPad®, OBN’s company showcase presentation session which will take place at BioTrinity 2019 on 30 April and 1 May.

Planning for BioSeed® 2020 is underway and details will be announced at a later date on www.bioseed.eu

ENDS

Contacts:

Event enquiries:

Jane O’Driscoll, Head of Events, OBN
jane.odriscoll@obn.org.uk

Communications:

Rebecca Wilkes, Communications & Marketing Co-ordinator, OBN
rebecca.wilkes@obn.org.uk

Media enquiries:

Citigate Dewe Rogerson
Sylvie Berrebi, Director;
Sylvie.berrebi@citigatedewerogerson.com
Shabnam Bashir
Shabnam.bashir@citigatedewerogerson.com

About OBN

OBN is the Membership organisation supporting and bringing together the UK’s emerging life sciences companies, corporate partners and investors. Our 400+ member companies are located throughout the UK and benefit from our networking, partnering, purchasing, advising and advocacy activities.

OBN delivers four World-Quality flagships events per annum:

BIOTRINITY®:

BioTrinity is Europe’s leading Biopartnering and Investment conference which will be held in London on 30th April and 1st May 2019 (its 13th year).

www.biotrinity.com

BIOSEED®:

BioSeed is a unique platform for early-stage life sciences companies, TTO’s, and Universities throughout Europe seeking equity investment from angels, HNW individuals, specialist crowd-funders, and PE / VC / Pharma funders genuinely interested in seed and series A funding (London, January 2020).

www.bioseed.eu

BIOFORWARD®:

BioForward is a high-quality international partnering conference providing a roadmap for R&D companies looking to achieve sustainable business growth (Birmingham, 11th October 2019).

www.bioforward.co.uk

OBN AWARDS:

This is the UK’s leading Life Sciences awards event, celebrating innovation and outstanding achievement across the UK Life Sciences Industry (Oxford, 7th November 2019).

www.obn-awards.com

Further information about OBN’s tailored networking and partnering events, purchasing consortium, advice, consultancy services and advocacy activities is available on OBN’s website www.obn.org.uk

Record changed: 2023-06-05